Phenotypes Associated with This Genotype

Genotype
MGI:2673126

• Allelic Composition: Cd2ap^tm1Shaw/Cd2ap^tm1Shaw
• Genetic Background: involves: 129X1/SvJ

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

premature death ( J:57971 )

• most dead between 6 and 7 weeks of age

cardiovascular system

enlarged heart ( J:57971 )

• hypertrophy

growth/size/body

enlarged heart ( J:57971 )

• hypertrophy

postnatal growth retardation ( J:57971 )

• evident beginning at about 3 weeks of age

hematopoietic system

decreased T cell proliferation ( J:57971 )

• in response to either concanavalin A (ConA) or CD3

thymus atrophy ( J:57971 )

spleen atrophy ( J:57971 )

homeostasis/metabolism

increased circulating creatinine level ( J:57971 )

• elevated in blood

decreased circulating serum albumin level ( J:57971 )

• decreased in serum

increased blood urea nitrogen level ( J:57971 )

• elevated

ascites ( J:57971 )

increased urine protein level ( J:57971 )

immune system

decreased T cell proliferation ( J:57971 )

• in response to either concanavalin A (ConA) or CD3

thymus atrophy ( J:57971 )

spleen atrophy ( J:57971 )

renal/urinary system

increased mesangial cell number ( J:57971 )

• hyperplasia

increased urine protein level ( J:57971 )

abnormal podocyte morphology ( J:57971 )

• loss of integrity between cells, evident at 1 week of age and progressive

glomerulosclerosis ( J:57971 )

• evident by 4 weeks of age

renal glomerulus hypertrophy ( J:57971 )

• increased size and cellularity, porgressivley worse with age

endocrine/exocrine glands

thymus atrophy ( J:57971 )

cellular

increased mesangial cell number ( J:57971 )

• hyperplasia

decreased T cell proliferation ( J:57971 )

• in response to either concanavalin A (ConA) or CD3